Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001

Tuesday, September 9, 2008 General News J E 4
WALTHAM, Mass., Sept. 8 Logical Therapeutics, Inc.,announced today the commencement of its double-blind, randomized,active-controlled, multinational study of LT-NS001, a novel prodrug, which isconverted in the bloodstream to naproxen, a non-steroidal anti-inflammatorydrug (NSAID). NSAIDs are the most common medications taken worldwide for thetreatment of pain, inflammation, fever and arthritis, including bothrheumatoid arthritis (RA) and osteoarthritis (OA).

"Despite a long history of successfully treating patients for pain andinflammation, NSAIDs have limitations that restrict their use.Gastrointestinal (GI) side effects are a significant safety problem," saidLutz Giebel, Chairman of Logical Therapeutics. Published studies have shownthat NSAID use is responsible for 15-60% of hospital admissions for GIbleeding, amounting to approximately 100,000 hospitalizations and10,000-20,000 deaths annually in the US. "A safer alternative would fulfill asignificant unmet medical need," Dr. Giebel went on to say.

In pre-clinical studies in rats and dogs, LT-NS001 was shown to causesignificantly less damage to the gastrointestinal tract than equivalent dosesof naproxen. The study will assess gastrointestinal injury by endoscopy after7 days of therapy. LT-NS001 was previously evaluated in two Phase 1randomized, placebo-controlled, single-dose and multiple-dose pharmacokineticstudies. In all cases, LT-NS001 was well tolerated. Moreover, when thesubjects were dosed twice daily with LT-NS001, plasma concentrations ofnaproxen were within the therapeutic range.

The Company also announced the departure of founding CEO, Dr. Mitchell P.Fink, who resigned to pursue other interests.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company basedin Waltham, Massachusetts. Logical Therapeutics is developing drugs to treata variety of medical conditions that are associated with excessiveinflammation, including osteoarthritis and rheumatoid arthritis. For moreinformation on Logical Therapeutics, visit the company's website or send an email to

SOURCE Logical Therapeutics, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Minnesota Health Information Exchange and Compuwar...
Competitive Intensity Grows in Alzheimer's Disease...